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Editor-in-Chief ’s NoteHuman Papillomavirus Infections, More on Colchicine, and
Some Farewells and WelcomesLet me begin by wishing one and all a happy and safer 2014. In
this issue, our Special Topic focus is on human papillomavirus
(HPV) infections in women (eg, genital warts and cervical cancer)
and their prevention through vaccination. The Centers for Disease
Control and Prevention (CDC) speciﬁcally recommend routine
HPV vaccination for girls at the age of 11 or 12 years. The series of
3 inoculations can be started at age 9 years, and it should be
completed by age 26 years.1 The most recent statistics from the
CDC survey for girls in the United States who are aged 13 to 17
years suggest that about one third have received the recommended
3 doses.2 Linda R. Duska, MD, our 2103 Topic Editor for
Women’s Health, has assembled 4 excellent reviews that
illustrate the status and value of comprehensive vaccination
programs in women.
I would be remiss if I did not point out that HPV infections are
also a serious and worldwide problem for men. Indeed, the
American Society of Clinical Oncologists predicts that mouth and
throat (oropharyngeal) cancers (speciﬁcally those that result from
HPV infection and not from smoking) in middle-aged men will exceed the number of cases of cervical cancer by
the year 2020.3 HPV-related oropharyngeal cancers can also occur in women. Some cases of penile cancer are also
now recognized as being caused by HPV.4 The CDC recommend HPV vaccination for boys (age 11–12 years) as
well as for teenage boys and young men up to the age of 21 years who did not receive it earlier.1 Statistics suggest
that boys are only now beginning to be vaccinated. The same survey for teens noted above reported that 6.8% of
boys aged 13 to 17 years were vaccinated in 2012.2
Improvement in our educational programs for parents and teens is clearly needed. Dr. Anees Chagpar recently
stated that “less than a third of people with a less than high school education are aware of a potentially cancer-
preventing vaccine; we know we can be doing better.”5
In August, we devoted the special focus to acute coronary syndromes. My editorial and one of the papers
commented on colchicine.6,7 Because colchicine is a prime example of an old agent undergoing repurposing,
I want to mention a few papers that appeared soon after our issue. In October, The New England Journal of
Medicine reported a randomized, placebo-controlled trial of colchicine in patients with acute pericarditis. The
results indicated that adding colchicine to standard antiinﬂammatory therapy had statistically and clinically
signiﬁcant value.8 In my editorial, I mentioned accidental poisoning with colchicine from ingested crocus plants. In
December, what appear to be the ﬁrst 2 reported cases of intoxication from the ingestion of colchicine with
suicidal intent were published.9 I recommend both of these articles to those wishing to follow the unfolding
colchicine story.
Our publishing team and I want to thank Drs. Linda R. Duska and Andreas K. Klein for their excellent efforts
and for providing scholarly triaging and review of articles in their respective areas during 2013. Each also
provided clinically valuable Special Focus issues. Dr. Duska will be continuing on with us in a new role as
Contributing Editor, and will provide additional support and collaboration on upcoming issues with a
concentration on women’s health topics.January 2014 1
Clinical TherapeuticsWe are expanding the Women’s Health area by adding to it Gender Medicine. The new topic will be called
Women’s Health and Gender Medicine, and we welcome our new Topic Editor, Jane F. Reckelhoff, PhD. Jane is
the Billy S. Guyton Distinguished Professor and the Director of the Women’s Health Research Center at the
University of Mississippi Medical Center. Formerly, she was the Editor-in-Chief of Gender Medicine, which is no
longer being published. Jane describes her topic as focusing on the study of sex and gender differences, with
particular attention to speciﬁc mechanisms involved in cardiovascular, renal, immune system, and other diseases
in women across the life span. We also welcome James W. Mier, MD, as our new Topic Editor for Oncology and
Hematology. Jim is Associate Professor of Medicine at Harvard Medical School, where he is heavily involved in
evaluating new oncologic therapies.Richard I. Shader
Editor-in-Chief
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